血小板参数和凝血指标的变化与肝硬化Child-Pugh分级的关系

目的了解肝硬化患者血小板参数和凝血指标的变化及其与肝功能Child-Pugh分级的关系。方法分别采用全自动血液分析仪和全自动血凝仪测定148例肝硬化患者和50例健康对照者的血小板参数(PLT、MPV、PDW、P-LCR)和凝血功能指标(PT、aPTT、TT、Fbg),比较肝硬化组与对照组、肝硬化Child-Pugh分级后组间及出血组与未出血组间血小板参数和凝血指标的变化。结果与对照组比较,肝硬化患者PLT下降,MPV、PDW、P-LCR升高,Fbg降低,PT、aPTT、TT延长,差异有统计学意义(P<0.01);随着Child-Pugh等级上升,其PLT逐渐下降,MPV、PDW、P-LCR逐渐升高,Fbg逐渐降低,PT、aPTT、TT逐渐延长(P<0.01);出血组与未出血组的血小板参数和凝血指标差异均有统计学意义(P<0.01)。结论肝硬化患者存在血小板及凝血功能异常,其血小板参数和凝血指标的变化与肝功能Child-Pugh分级和出血与否密切相关,是判定肝硬化损害程度及出血倾向的重要指标。     

老年肝硬化患者凝血及血小板功能变化与Child-Pugh分级的关系

目的 探讨老年肝硬化患者凝血及血小板指标的变化及其与Child-Pugh分级的关系.方法 肝硬化患者67例,Child-Pugh分级A级21例,B级24例,C级22例;正常对照组22例.全部受试者均检测凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(FIB)、血小板计数(PLT)、血小板压积(PCT)、平均血小板体积(PCV)、血小板体积分布宽度(PDW),并进行对照分析.结果 老年肝硬化组与正常对照组比较,PLT、PCT显著下降(均P＜0.001),MPV、PDW显著升高(均P＜0.001);肝功能B、C 级与A 级比较,C级PLT 和PCT下降显著(均P＜0.01),MPV、PDW显著升高(均P＜0.01);老年肝硬化患者PT、APTT 均较对照组明显延长(均P＜0.001),FIB 明显降低(P＜0.01).结论 老年肝硬化患者存在明显的凝血、血小板异常,且与肝硬化程度密切相关.     

肝硬化患者血小板参数和凝血指标变化及与肝功能Child-Pugh分级的关系

目的 观察肝硬化患者血小板参数和凝血指标变化及其临床意义.方法 选择同期收治的肝硬化患者132例（肝硬化组）及一般资料与其匹配的健康查体者45例（对照组）,分别采用全自动血细胞计数仪检测血小板参数包括血小板计数（PLT）、平均血小板体积（MPV）、血小板分布宽度（PDW）、血小板压积（PCT）;采用全自动血凝仪检测凝血指标包括活化部分凝血酶原时间（APTT）、凝血酶原时间（PT）、凝血酶时间（TT）、纤维蛋白原（Fig）.结果 肝硬化组MPV、PDW明显高于对照组,而PLT、PCT明显低于对照组,且随肝功能Child-Pugh分级加重PLT、PCT逐渐降低,而MPV、PDW逐渐升高（P均＜0.05）;肝硬化组APTT、PT、TT明显高于对照组,而Fig明显低于对照组,且随肝功能Child-Pugh分级加重APTT、PT、TT逐渐升高,而Fig逐渐降低（P均＜0.05）.结论 肝硬化患者血小板参数与凝血指标均有异常变化,且与肝功能Child-Pugh分级密切相关;此对临床了解肝硬化患者肝功能损害程度及判断出血倾向具有重要参考价值.     

血小板参数和凝血指标与溶栓治疗关系的探讨

目的 动态观察急性脑梗死患者溶栓治疗过程中血小板参数及凝血指标的变化规律,探讨血小板参数和凝血指标与溶栓治疗的关系.方法 应用血细胞分析仪检测180例急性脑梗死患者（实验组）和180例健康体检者（对照组）的血小板计数（PLT）、血小板平均体积（MPV）和大血小板比率（P-LCR）,血凝分析仪检测凝血酶原时间（PT）、部分活化凝血活酶时间（APTT）、纤维蛋白原（Fg）及凝血酶时间（TT）,动态观察溶栓前及溶栓后1、2、4小时和48小时血小板参数和凝血指标的变化.结果 溶栓前脑梗死患者的MPV、P-LCR和Fg含量均高于对照组（P均＜0.05）,PLT、PT和APTT显著低于对照组（P均＜0.05）;溶栓治疗后,MPV、P-LCR和Fg含量显著下降,PLT、PT和APTT显著升高（P均＜0.05）.结论 溶栓治疗过程中,动态监测急性脑梗死患者的血小板参数（PLT、MPV和P-LCR）和凝血指标（PT、APTT、Fg）,可反映患者凝血功能的变化,对脑梗死患者的溶栓治疗具有一定的参考价值.     

肝硬化患者凝血指标、血清前白蛋白和总胆汁酸检测的临床价值

目的探讨检测肝硬化患者凝血指标、血清前白蛋白(PA)和总胆汁酸(TBA)的临床价值。方法检测了165例肝硬化患者(肝硬化组)和50例健康者(对照组)的凝血功能指标(PT、aPTT、TF、Fbg)和肝功能(ALT、TBIL、PA、ALB、TBA),并根据肝功能Child-Pugh分级进行分组比较。结果与对照组比较,肝硬化组PT,aPTT、TT延长,Fbg降低,ALT、TBIL、TBA升高,PA、ALB降低(P<0.01);随着患者Child-Pugh分级增高,其PT,aPTT、TT逐渐延长,Fbg逐渐降低,TBIL TBA逐渐升高,PA、ALB逐渐降低,不同级别间差异有统计学意义(P<0.05,P<0.01)。结论凝血指标、血清前白蛋白和总胆汁酸反映患者肝脏的合成功能,可作为评估肝硬化患者病情及预后的有效指标。     

肝硬化患者血小板参数、凝血指标与上消化道出血的相关性

目的 探讨肝硬化患者血小板参数、凝血指标与上消化道出血的相关性。方法 选择2020年1月至2021年1月聊城市人民医院收治的肝硬化合并上消化道出血患者45例(A组),肝硬化不合并上消化道出血患者的57例(B组),选择同期健康体检者49名(C组)。比较3组的血清血小板计数(PLT)、血小板平均体积(MPV)、血小板比容(PCT)、血小板分布宽度(PDW)、活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、凝血酶时间(TT)、纤维蛋白原(FIB)的表达水平,采用Pearson相关分析血清PLT、MPV、PCT、PDW、APTT、PT、TT、FIB与上消化道出血的相关性。结果 A组PLT、MPV、PCT、PDW水平分别为(301.16±50.24)×10⁹/L、(8.37±1.34)fL、(0.25±0.06)%、(19.00±1.27)%,明显高于B组的(330.03±55.28)×10⁹/L、(9.38±1.50)fL、(0.35±0.10)%、(22.02±1.49)%和C组(200.15±40.30)×10⁹/L...     

脑梗死患者血脂、血小板参数、部分凝血指标变化及意义

脑梗死的发病机制日益受到临床关注。我们检测了 4 0例脑梗死患者的血脂水平、血小板参数及部分凝血指标 ,旨在探讨其与脑梗死发病的相关性。资料与方法 :脑梗死组为 4 0例脑梗死患者 (男 35例 ,女5例 ,平均年龄 6 5岁 ) ,根据临床症状、神经系统体检和 CT检查结果确诊 ,符合全国第二次脑血管病学术会议诊断标准(1986年 ) ,且未经任何溶栓治疗。对照组为 30例健康查体者(男 2 2例 ,女 8例 ,平均年龄 5 8岁 )。两组均抽取静脉血 ,分别测定血脂、血小板参数及部分凝血指标。表 1　两组相关指标检测结果比较 (x± s)　检测指标　脑梗死组　对…     

肝硬化患者Child-Pugh分级与血小板生成素的关系

目的:探讨肝硬化患者Child-Pugh分级与血小板生成素(TPO)的关系.方法:选取肝硬化患者119例,另选取与肝硬化组性别和年龄相匹配的30例健康人作为对照组;晨起空腹采血、离心分离血清,检测血液常规、血液生化、血离子、肝炎病毒标志物,肝脾B超检查:用ELISA法检测血清TPO含量.结果:肝硬化患者中Child-Pugh A、B、C级分别为43例、63例和13例.与对照组相比,肝硬化患者平均TPO水平无显著性差异,A级TPO水平有升高的趋势,但无统计学意义,而B级(43.44 ng/L±33.51 ng/L)和C级(45.16 ng/L±30.04 ng/L)则明显降低(P=0.001,0.048);血小板计数(PLT)在A级、B级和C级逐渐下降,与对照组相比,均有显著性差异(均P<0.001);TPO与PLT在对照组呈负相关(r=.0.363,P=0.048),在Child-Pugh A级和C级两者无相关性,在B级呈正相关且有统计学意义(r=0.383,P=0.002).结论:肝脏合成TPO减少是晚期肝硬化患者血小板减少的重要原因:TPO和PLT可以作为反应肝脏功能的指标.     

肝硬化患者血小板参数的变化及其临床意义

探讨肝硬化患者出凝血系统的变化及导致出血的原因,采用K4500全自动血球计数仪对60例肝硬化患者进行血小板参数检测,发现肝硬化患者血小板计数(PLT)平均血小板体积(MPV)及血小板压积(PCT),血小板分布宽度(PDW),与对照组相比均有显著性差异(P<0.01和P<0.05),出血组与非出血组比较PLT、PCT、MPV亦有显著差异(P<0.01)。血小板四项参数对肝硬化患者血小板功能及出凝血异常的判断有一定的参考价值,可作为衡量肝硬化出血倾向的重要指标之一。     

肝硬化患者的血小板参数检测及其临床意义

乙型病毒性肝炎后肝硬化的病人血小板减少是众所周知的。由于乙型肝炎病毒(HBV)感染后,可损害骨髓的造血功能和机体的免疫功能,引起不同程度的单核-巨噬细胞系统功能减弱,脾功能亢进,尤其是HBV抑制巨核细胞增殖,在病毒或毒素的作用下会导致血小板超微结构的异常。为了解肝硬化患者血小板的变化情况,     

Correlation between hepatic blood flow and coagulation indices in chronic active hepatitis and liver cirrhosis patients

Hepatic blood flow (HBF) has been reported to reflect liver cell mass. HBF was studied in 21 patients with chronic active hepatitis (CAH) and in 20 patients with liver cirrhosis (LC). It was correlated with such indices of liver protein synthesis as serum albumin, Normotest, plasma activity of antithrombin III, prekallikrein, alpha 2-antiplasmin and plasminogen. No correlation between HBF and the examined parameters was seen in CAH. HBF correlated with all the indices of liver protein synthesis in LC, thus suggesting that serum albumin, antithrombin III, Normotest, prekallikrein, plasminogen, and alpha 2-antiplasmin could reflect the residual liver cell mass in LC.     

晚期血吸虫病肝硬化和乙型肝炎肝硬化患者凝血相关参数比较分析

目的比较、分析晚期血吸虫病肝硬化和乙型肝炎肝硬化患者凝血功能相关参数在不同肝功能分级下的差异,为临床病情及预后的判断提供进一步的指导依据。方法选择荆州市中心医院2014年1月-2016年6月期间住院的晚期血吸虫病肝硬化患者63例、乙型肝炎肝硬化患者80例分别作为血吸虫肝硬化组和乙肝肝硬化组;选择同期因胃病住院并排除患其他可能影响凝血功能疾病的患者96例作为对照组,检测并比较3组凝血相关参数值,以及不同Child-Pugh分级下晚期血吸虫病肝硬化和乙型肝炎肝硬化患者相关参数值。结果 3组凝血酶原时间(PT)、国际标准化比率(INR)、纤维蛋白原(Fib)、凝血酶时间(TT)、活化部分凝血活酶时间(APTT)、血小板(PLT)水平差异均有统计学意义(F=84.512、81.672、37.612、104.475、52.497、102.233,P均0.05)。两两比较显示,血吸虫病和乙肝肝硬化患者的PT、INR、TT、APTT均较对照组明显延长,PLT均明显减少,差异均有统计学意义(P均0.05)。与血吸虫病肝硬化组相比,乙肝肝硬化患者PT、INR、TT、APTT时间均明显延长,Fib及PLT明显下降,差异均有统计学意义(P均0.05)。肝功能分级为Child-Pugh A级时,乙肝肝硬化患者PLT减少程度较重;但当肝功能分级为Child-Pugh B、C级时,2组患者PLT计数差异无统计学意义(P均0.05)。各分级下,乙肝肝硬化组TT、APTT均较血吸虫病肝硬化组延长,且Fib水平均明显下降。而乙肝肝硬化组PT、INR值仅在肝功能为Child-Pugh A、B级时较血吸虫病肝硬化组延长;在肝功能为C级时,两组差异无统计学意义(P均0.05)。结论晚期血吸虫病肝硬化患者和乙型肝炎肝硬化患者凝血功能损害程度存在差异。在肝功能受损程度较轻时,后者凝血功能下降更明显;肝功能受损严重时,后者内源性凝血途径的影响更为明显,外源性凝血途径的影响及PLT减少在两类患者中差异不大。     

乙型肝炎后肝硬化患者血小板参数的临床分析

目的 观察血小板参数变化与乙型肝炎后肝硬化的关系并探讨其临床意义。方法 乙型肝炎后肝硬化患者135例（A组）和健康体检者82例（B组）采用全自动血细胞分析仪检PLT、血小板比容（PCT）、平均血小板体积（MPV）、血小板分布宽度（PDW）。A组患者根据有无上消化道出血分为合并上消化道出血组（C组,65例）和无上消化道出血组（D组,70例）,分别比较各组参数情况。结果 A组PLT、PCT均显著低于B组（P均=0.006）,其MPV、PDW均高于B组（P均=0.007）。C组PLT、PCT、MPV、PDW均低于D组（P均〈0.05）。结论 血小板参数的测定对评估肝硬化患者肝功能损害程度、判断有无出血倾向具有重要的指导意义。     

乙型肝炎肝硬化失代偿期与酒精性肝硬化失代偿期患者血小板参数变化的临床分析

目的探讨不同HBV DNA水平乙型肝炎肝硬化失代偿期与酒精性肝硬化失代偿期血小板计数（PLT）及血小板平均体积（MPV）变化的临床意义。方法对36例健康人、38例HBV DNA〈105拷贝/ml乙型肝炎肝硬化失代偿期患者、36例HBV DNA〉105拷贝/ml乙型肝炎肝硬化失代偿期患者及31例酒精性肝硬化失代偿期患者的外周血PLT及MPV进行测定及分析。结果与健康人相比,乙型肝炎肝硬化及酒精性肝硬化患者PLT均下降,差异有统计学意义（P〈0.05）;与酒精性肝硬化失代偿期患者相比,HBV DNA〉105拷贝/ml乙型肝炎肝硬化失代偿期患者PLT下降,差异有统计学意义（P〈0.05）;不同HBV DNA水平的乙型肝炎肝硬化失代偿期患者PLT均下降,差异有统计学意义（P〈0.05）。与健康人相比,酒精性肝硬化失代偿期、HBV DNA〉105拷贝/ml乙型肝炎肝硬化失代偿期患者MPV均下降,差异有统计学意义（P〈0.05）;与酒精性肝硬化失代偿期患者相比,HBV DNA〉105拷贝/ml乙型肝炎肝硬化失偿代期患者MPV下降,差异有统计学意义（P〈0.05）;不同HBV DNA水平的乙型肝炎肝硬化失代偿期患者MPV变化,差异有统计学意义（P〈0.05）。结论乙型肝炎肝硬化失代偿期患者高载量HBV DNA对血小板参数降低有一定的影响。     

Preoperative coagulation indices in patients with morbid obesity

Preventive measures against venous thromboembolism are used frequently in surgical patients with morbid obesity because the risk has been claimed to be higher than usual. We addressed this risk in 81 morbidly obese patients by measuring preoperative plasma proteins associated with coagulation and by correlating variations in these indices to excess weight, liver histology, patient sex, tobacco use and serum triglycerides. Plasma levels of antithrombin III and plasminogen were normal in these patients. Plasma fibrinogen concentrations were elevated in 34 percent of patients; the values did not relate to excess weight and they correlated negatively (P less than 0.04) with increasing serum triglycerides and grades of liver fat content. Premenopausal women had higher plasminogen and fibrinogen levels than menopausal women or men, although their mean levels were normal. Smokers had lower plasminogen levels than nonsmokers (P less than 0.01). However, none of the measured levels of preoperative coagulation proteins identified increased risk for venous thrombosis in cohorts of this population, and the coagulation indices were not different from those reported in normal weight patients.     

Correlation between platelet blood levels and the hepatic venous pressure gradient among patients with cirrhosis

BACKGROUND: Determination of hepatic venous pressure gradient is the main method used to assess portal pressure. Recently, platelet blood levels has been indicated as a non-invasive marker of the presence of portal hypertension. AIM: To correlate platelet blood levels with the hepatic venous pressure gradient among patients with cirrhosis. PATIENTS AND METHODS: A total of 83 cirrhotic patients who had undergone hepatic venous pressure gradient over the last 6 years were included. Patients were divided in groups according to Child-Pugh classification. All had upper digestive endoscopy to assess the presence of esophageal varices and platelet serum levels were recorded. RESULTS: Platelet serum levels range varied between 45,000/mm(3) and 389,000/mm(3) (mean: 104,099; standard deviation: 58,776). Mean hepatic venous pressure gradient was 15.2 mm Hg with a standard deviation of 6.4 mm Hg (range: 1 to 29 mm Hg). Simple linear regression analysis was applied to verify an association of hepatic venous pressure gradient and platelet serum levels, revealing a weak correlation between both variables. We observed a progressive reduction of serum platelet levels as esophageal varices diameter increased and hepatocellular function (established by Child-Pugh classification) decreased. However, these findings did not reach statistical significance. CONCLUSION: Despite the lack of a statistical significant correlation among serum platelet levels and hepatic venous pressure gradient or hepatocellular function, there was a clear tendency indicating that those variables could be involved in the pathogenesis of low platelet levels.     

Correlation of routinely used coagulation parameters and presence of portal vein thrombosis in patients with liver cirrhosis

Aim:  Portal vein thrombosis (PVT) is a serious complication in patients with liver cirrhosis. In patients with advanced stages of liver cirrhosis plasmatic coagulation and platelet count are often reduced. However, patients with normal coagulation status might carry a high risk for developing PVT. A correlation between coagulation status used in clinical routine and the incidence of PVT in patients with liver cirrhosis has been evaluated in the present retrospective analysis.
Methods:  88 patients with liver cirrhosis were identified by screening a database. Of these patients, 23 suffered from PVT. Patients were classified according to the Child–Pugh classification. Patients were subdivided into early stages (Child A) and advanced stages (Child B/C) of liver cirrhosis.
Results:  In patients with Child–Pugh A cirrhosis, there was no difference in activated partial thromboplastin time (apTT), international normalized ratio (INR), and platelet count between the PVT ( n  = 7) and the control group ( n  = 35). In contrast, the median apTT and INR were significantly lower in patients with Child B/C cirrhosis and PVT ( n  = 16) in comparison with patients without PVT (37 s vs 43 s [ P  = 0.017] and 1.25 vs 1.40 [ P  = 0.022]), respectively. Platelet count did not differ significantly in patients with advanced liver cirrhosis and PVT from those without PVT.
Conclusion:  Patients with advanced liver cirrhosis and PVT displayed lower apTT and INR compared with those without PVT. Therefore, patients with advanced liver cirrhosis and almost normal coagulation parameters might be at particular risk of developing PVT. The results suggest that regular monitoring using Doppler-ultrasound should be carried out in these patients, especially when liver transplantation is intended.     

Reduced platelet activation and platelet aggregation in patients with alcoholic liver cirrhosis

Results from previous studies regarding platelet function in liver cirrhosis are discordant. The aim was to investigate platelet activation and platelet aggregation in patients with alcoholic liver cirrhosis. We included 27 patients with alcoholic liver cirrhosis and 22 healthy individuals. A recently established flow cytometric approach was used to measure platelet activation and platelet aggregation independent of sample platelet count. Platelet aggregation was further investigated using light transmission aggregometry (LTA) (for platelet count >100 × 10⁹/L). Platelet agonists were adenosine diphosphate, thrombin receptor-activating peptide, arachidonic acid, collagen, and collagen-related peptide. Patients had lower median platelet count than healthy individuals, 125 × 10⁹/L (interquartile range [IQR] 90?185) versus 240 × 10⁹ (IQR 204?285), p < 0.001. Platelet activation levels in stimulated samples were lower in patients versus healthy individuals, e.g., after collagen-related peptide stimulation, the median percentage of platelets positive for activated glycoprotein IIb/IIIa was 85% (IQR 70–94) in patients versus 97% (IQR 94–99) in healthy individuals, p < 0.001; lower platelet activation capacity being associated with low platelet count and Child–Pugh class B/C cirrhosis. Flow cytometric platelet aggregation was reduced in patients for collagen-related peptide and for adenosine diphosphate, e.g., platelet aggregation (mean ± standard deviation) was 57% ± 4 in patients versus 70% ± 1 in healthy individuals for collagen-related peptide, p = 0.01. Light LTA showed reduced collagen-induced platelet aggregation in some patients compared with healthy individuals. In conclusion, platelet function was reduced in some patients with alcoholic liver cirrhosis and the severity was associated with platelet count and severity of liver cirrhosis.